Acura Pharmaceuticals, Inc Email Format

Pharmaceutical ManufacturingIllinois, United States2-10 Employees

Acura Pharmaceuticals, Inc. is a small specialty pharmaceutical company based in Palatine, Illinois, focused on the research, development, and commercialization of technologies aimed at reducing medication abuse and misuse. It pursues multiple proprietary approaches intended to deter abuse while preserving therapeutic benefit, with products brought to market to address misuse in pain relief and related areas. The company’s collaboration history includes OXAYDO, a branded oxycodone product that became the first approved offering to employ its abuse-deterrent approach in the United States; in 2015, Acura granted Egalet US exclusive worldwide rights to manufacture and market OXAYDO, which had FDA approval for 5 mg and 7.5 mg strengths and was launched later that year. It operates with a small team and maintains ongoing development activities in this space.
Additionally, the company has launched NEXAFED Decongestant products that employ an abuse-deterrent approach, with NEXAFED Decongestant with Impede Technology introduced in 2012 and NEXAFED Sinus Pressure + Pain following in 2015. It continues to develop other pseudoephedrine products using this approach. Acura situates itself in the pharmaceutical manufacturing sector as a niche provider focused on abuse-deterrent solutions for prescription medications.

Get verified Acura Pharmaceuticals, Inc emails free

Company overview Employee directory